PA8802301A1 - Compuestos que exhiben actividad antagonista del glucagon y agonistas del glp-1 - Google Patents

Compuestos que exhiben actividad antagonista del glucagon y agonistas del glp-1

Info

Publication number
PA8802301A1
PA8802301A1 PA20088802301A PA8802301A PA8802301A1 PA 8802301 A1 PA8802301 A1 PA 8802301A1 PA 20088802301 A PA20088802301 A PA 20088802301A PA 8802301 A PA8802301 A PA 8802301A PA 8802301 A1 PA8802301 A1 PA 8802301A1
Authority
PA
Panama
Prior art keywords
glucagon
glp
agonists
compounds
antagonist activity
Prior art date
Application number
PA20088802301A
Other languages
English (en)
Inventor
Yang Bin
Ouyang Chenguang
Dimarchi Richard
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of PA8802301A1 publication Critical patent/PA8802301A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DIVULGAN ANÁLOGOS DE GLUCAGÓN QUE PRESENTAN ACTIVIDAD TANTO ANTAGONISTA DE GLUCAGÓN COMO AGONISTA GLP-1. EN UNA REALIZACIÓN, EL ANTAGONISTA DE GLUCAGÓN/AGONISTA GLP-1 COMPRENDE UNA SECUENCIA MODIFICADA DE AMINOÁCIDOS DEL GLUCAGÓN NATIVO, EN EL CUAL SE SUPRIME DESDE EL PRIMERO AL QUINTO AMINOÁCIDO N-TERMINAL DE GLUCAGÓN NATIVO Y EN EL CUAL SE ESTABILIZA EL HÉLICE ALFA.
PA20088802301A 2007-10-30 2008-10-30 Compuestos que exhiben actividad antagonista del glucagon y agonistas del glp-1 PA8802301A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98376607P 2007-10-30 2007-10-30
US9044108P 2008-08-20 2008-08-20

Publications (1)

Publication Number Publication Date
PA8802301A1 true PA8802301A1 (es) 2009-06-23

Family

ID=40591418

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088802301A PA8802301A1 (es) 2007-10-30 2008-10-30 Compuestos que exhiben actividad antagonista del glucagon y agonistas del glp-1

Country Status (14)

Country Link
US (1) US8980830B2 (es)
EP (1) EP2214691B1 (es)
JP (1) JP5771005B2 (es)
AR (1) AR069136A1 (es)
AU (1) AU2008318876B2 (es)
CA (1) CA2702289A1 (es)
CL (1) CL2008003243A1 (es)
ES (1) ES2558155T3 (es)
HK (1) HK1141984A1 (es)
MX (1) MX2010004298A (es)
PA (1) PA8802301A1 (es)
PE (1) PE20090932A1 (es)
TW (1) TW200920395A (es)
WO (1) WO2009058734A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
EP2487184A1 (en) 2007-02-15 2012-08-15 Indiana University Research and Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
JP5669582B2 (ja) 2007-10-30 2015-02-12 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation グルカゴンアンタゴニスト
WO2009099763A1 (en) * 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
EP2952202B1 (en) 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation 生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
CN102459325B (zh) * 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
EP2501685A1 (en) 2009-11-16 2012-09-26 Mellitech [1,5]-diazocin derivatives
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐gipアゴニスト複合体及び組成物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
MX2012013001A (es) * 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Gタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
MX2012014576A (es) 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2635296B1 (en) 2010-11-03 2014-12-24 Arecor Limited Novel composition comprising glucagon
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
WO2012169798A2 (en) 2011-06-10 2012-12-13 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
PE20141178A1 (es) 2011-06-17 2014-09-12 Hanmi Science Co Ltd Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2729493B1 (en) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2780031B1 (en) 2011-11-17 2018-03-07 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
CN104185639B (zh) 2012-03-01 2018-06-19 诺和诺德股份有限公司 Glp-1前体药物
CN104302772B (zh) 2012-05-18 2017-11-10 爱德迪安(北京)生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
EP2916819B1 (en) 2012-11-06 2019-07-10 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
TWI674270B (zh) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
ES2688367T3 (es) 2012-12-21 2018-11-02 Sanofi Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽-4(exendin-4)胜肽類似物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
MX2017005280A (es) 2014-10-24 2017-08-15 Merck Sharp & Dohme Coagonistas de los receptores de glucagon y de glp-1.
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
CN105801705B (zh) * 2014-12-31 2019-05-24 天境生物科技(上海)有限公司 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US10800826B2 (en) 2015-10-05 2020-10-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
US11510993B2 (en) 2015-10-06 2022-11-29 Merck Sharp & Dohme Llc Antibody drug conjugate for anti-inflammatory applications
EP3407916B1 (en) 2016-01-29 2023-12-20 Merck Sharp & Dohme LLC Phosphonate linkers and their use to facilitate cellular retention of compounds
WO2017210168A1 (en) * 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Aqueously soluble and chemically stable depsi glucagon agonists
EP3463424A4 (en) * 2016-06-02 2019-04-10 Indiana University Research & Technology Corporation Glucagon-Like Peptide-1 T3 CONJUGATES
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
WO2018151743A1 (en) * 2017-02-15 2018-08-23 Bioprocessia Technologies Llc Affinity chromatography ligands with mild elution ph
US11590237B2 (en) 2017-05-18 2023-02-28 Merck Sharp & Dohme Llc Pharmaceutical formulation comprising incretin-insulin conjugates
CN109836503B (zh) * 2017-11-24 2022-09-16 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
AU2019247936C1 (en) 2018-04-05 2023-06-15 Sun Pharmaceutical Industries Limited Novel GLP-1 analogues
CN111269321B (zh) * 2018-12-04 2023-05-12 鲁南制药集团股份有限公司 一种glp-1类似物融合蛋白质
US20230390250A1 (en) * 2020-10-30 2023-12-07 Robin Elaine DUNCAN Modulation of glucagon-like peptide 1 and uses thereof

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275152A (en) 1977-02-03 1981-06-23 Eastman Kodak Company Hydrolysis of protein-bound cholesterol esters
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
AU642403B2 (en) 1989-02-17 1993-10-21 Coselco Mimotopes Pty Ltd Method for the use and synthesis of peptides
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
CA2024855C (en) 1990-09-07 1997-12-09 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Process and intermediates for producing glucagon
JPH04145099A (ja) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Gip様活性を有するポリペプチド誘導体及びその用途
US5510459A (en) 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en) 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
HUP9801834A3 (en) 1995-10-12 2000-06-28 Supergen Inc Emeryville Liposome formulations of 5beta steroids
WO1997029180A1 (en) 1996-02-06 1997-08-14 Eli Lilly And Company Diabetes therapy
BR9710452A (pt) 1996-06-05 1999-08-17 Boehringer Mannheim Gmbh Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
AU724326B2 (en) 1996-09-09 2000-09-14 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
KR20050037004A (ko) 1998-12-07 2005-04-20 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Glp-1의 유사체
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
CA2367856C (en) 1999-03-29 2013-10-15 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
CA2405900A1 (en) 2000-04-27 2001-11-01 Bionebraska, Inc. Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
AU2001269833A1 (en) 2000-06-14 2001-12-24 Cytovax Biotechnologies, Inc. Use of coiled-coil structural scaffold to generate structure-specific peptides
DZ3388A1 (fr) 2000-06-16 2001-12-27 Lilly Co Eli Analogues de peptide 1 du type glucagon
US20030204063A1 (en) 2000-08-02 2003-10-30 Denis Gravel Modified biological peptides with increased potency
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
AU2001296962A1 (en) 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
EP1351984A2 (en) 2000-12-13 2003-10-15 Eli Lilly And Company Amidated glucagon-like peptide-1
EP1411968B1 (en) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
AU2002327430A1 (en) 2001-08-08 2003-02-24 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
RU2353625C2 (ru) 2001-10-18 2009-04-27 Бристол-Маерс Сквибб Компани Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний
JP2005508360A (ja) 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー Glp−1およびインスリンの二相混合物
EP1461069A2 (en) 2001-12-29 2004-09-29 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
AU2003200839B2 (en) 2002-01-08 2008-12-11 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
AU2003239478A1 (en) 2002-06-04 2003-12-22 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
EP1515746A2 (en) 2002-06-11 2005-03-23 Eisai Co. Ltd Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
EP1526864A4 (en) 2002-06-15 2006-11-08 Enteromed Inc PREVENTION AND TREATMENT OF NON-ALCOHOLIC FAT TREATMENT DISEASE (NAFLD) BY ANTAGONISM OF THE RECEPTOR OF GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE (GIP)
EP1539210A4 (en) 2002-09-06 2006-06-07 Bayer Pharmaceuticals Corp GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050059605A1 (en) * 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
CA2518336A1 (en) 2003-03-19 2004-11-04 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
CA2843439A1 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004240630B2 (en) 2003-05-15 2010-10-07 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
MXPA05013048A (es) 2003-06-03 2006-03-02 Novo Nordisk As Composiciones peptodicas farmaceuticas estabilizadas.
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー/エス 安定化された薬学的ペプチド組成物
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Glp−1アナログ複合タンパク質
WO2004111078A2 (en) 2003-06-18 2004-12-23 Theratechnologies Inc. Compounds that modulate the glucagon response and uses thereof
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
US7364875B2 (en) 2003-10-30 2008-04-29 Cresent Innovations, Inc. Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
DE602004026113D1 (de) 2003-12-18 2010-04-29 Novo Nordisk As Glp-1-verbindungen
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
EP1853627A2 (en) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
JP2008533104A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Glp−1受容体の二量体ペプチドアゴニスト
WO2006121904A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
JP5225074B2 (ja) 2005-05-13 2013-07-03 イーライ リリー アンド カンパニー Glp−1peg化化合物
RU2485135C2 (ru) 2005-06-13 2013-06-20 Импиэриэл Инноувейшнс Лимитид Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
CA2623412A1 (en) 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
US20090170762A1 (en) 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US7928058B2 (en) 2006-02-22 2011-04-19 Merck Sharp & Dohme Corp. Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
AU2007220775A1 (en) * 2006-02-28 2007-09-07 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
EP2574624A1 (en) 2006-04-20 2013-04-03 Amgen Inc. GLP-1 compounds
WO2008022015A2 (en) 2006-08-11 2008-02-21 Trustees Of Tufts College Retro-inverso incretin analogues, and methods of use thereof
CA2660835A1 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
EP2102355B1 (en) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
EP2487184A1 (en) 2007-02-15 2012-08-15 Indiana University Research and Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
US7859468B2 (en) * 2007-08-30 2010-12-28 Research In Motion Limited Mobile wireless communications device including a folded monopole multi-band antenna and related methods
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
JP2010538049A (ja) 2007-09-05 2010-12-09 ノボ・ノルデイスク・エー/エス 切断型glp−1誘導体及びその治療的使用
EP2200626A4 (en) 2007-09-07 2012-02-15 Ipsen Pharma Sas ANALOGUE OF EXENDIN-4 AND EXENDIN-3
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
WO2009034117A1 (en) 2007-09-11 2009-03-19 Novo Nordisk A/S Mixture comprising an amylin peptide and a protracted insulin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
JP5669582B2 (ja) 2007-10-30 2015-02-12 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation グルカゴンアンタゴニスト
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
US20090181037A1 (en) 2007-11-02 2009-07-16 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
CN101980725B (zh) 2008-02-01 2013-06-12 阿森迪斯药物股份有限公司 包含可自裂解的连接体的前药
EP2952202B1 (en) 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation 生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
RU2578591C2 (ru) 2008-12-19 2016-03-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Лекарственные средства, связанные с дипептидами
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
CN102459325B (zh) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐gipアゴニスト複合体及び組成物
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Gタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
MX2012013001A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
MX2012014576A (es) 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers

Also Published As

Publication number Publication date
ES2558155T3 (es) 2016-02-02
HK1141984A1 (en) 2010-11-26
CA2702289A1 (en) 2009-05-07
EP2214691A1 (en) 2010-08-11
AU2008318876A1 (en) 2009-05-07
EP2214691B1 (en) 2015-09-30
CL2008003243A1 (es) 2009-02-27
MX2010004298A (es) 2010-05-03
AR069136A1 (es) 2009-12-30
EP2214691A4 (en) 2011-01-05
JP5771005B2 (ja) 2015-08-26
WO2009058734A1 (en) 2009-05-07
PE20090932A1 (es) 2009-07-15
US20110098217A1 (en) 2011-04-28
TW200920395A (en) 2009-05-16
AU2008318876B2 (en) 2014-05-15
US8980830B2 (en) 2015-03-17
WO2009058734A4 (en) 2009-07-23
JP2011502159A (ja) 2011-01-20

Similar Documents

Publication Publication Date Title
PA8802301A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonistas del glp-1
CR11511A (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
ES2528347T3 (es) Derivado peptídico insulinotrópico en el que se ha modificado su aminoácido n-terminal
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
PE20150200A1 (es) Formulacion de anticuerpos
DOP2010000209A (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
GT201200144A (es) Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina
PE20150900A1 (es) Derivados de exendida-4 como agonistas duales de glp1/glucagon
AR092873A1 (es) Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
PA8811501A1 (es) Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado
NZ740644A (en) Glucagon receptor agonists
EA201490070A1 (ru) Коантагонисты глюкагонового рецептора/glp-1-рецептора
CL2019000043A1 (es) Nuevos análogos de urocortina-2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal crónica.
EA201491898A1 (ru) Варианты оксинтомодулина пролонгированного действия и способы получения указанных вариантов
CO6531500A2 (es) Composiciones y metodos para el tratamiento de la xerostomia
CL2012001298A1 (es) Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras.
PE20142114A1 (es) Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos
CL2012002706A1 (es) Composicion farmaceutica termogelificante estabilizada compuesta por anestesicos locales con un ph de al menos el pka de dichos anestesicos, que comprende a) la forma basica de uno o mas anestesicos de tipo amida, b) 10 a 30% de un aceite de ricino polioxietilado, y c) al menos 15% de uno o mas tensioactivos; y su metodo de preparacion.
EA201390182A1 (ru) Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
AR087093A1 (es) Composicion que mejora la palatabilidad que comprende aminoacidos libre para usar en alimentos para mascotas
PE20190117A1 (es) Compuestos de mic-1 y usos de estos
AR082422A1 (es) Composicion detergente liquida
AR102445A1 (es) COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA
UY33578A (es) PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS